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Propensity score matched cumulative one year costs
Variable
EES BMS Difference p for
(N  714) (N  714) (95% CI) Difference
Index stenting
cost, $
2288 1104
[1,650]
1107528
[800]
1181
(1094 to 1274)
0.001
Follow-up costs
Repeat
revascularization
cost, $
917 7551
[0]
2086 9395
[0]
-1169
(-2105 to -344)
0.010
Clopidogrel
therapy cost, $
1939 562
[2139]
1496 862
[2139]
443
(367 to 511)
0.001
Aggregate 1-year
cost, $
5145 7612
[3789]
4689 9436
[2939]
456
(-508 to 1291)
0.32
Assuming
generic
clopidogrel cost,
$*
3537 7662
[2015]
3448 9429
[1165]
88
(-864 to 922)
0.85
Values in brackets are medians. *Cost of generic clopidogrel assumed as $1/day.
Conclusions: In this prospective observational registry, the cost per TLR avoided with
EES was $10,000. With the advent of generic thienopyridine availability, the cost
effectiveness profile shifts significantly in favor of EES, with similar 1-year aggregate
costs compared to BMS.
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Background: The efficacy and safety of XIENCE V® everolimus-eluting coro-
nary stents (XIENCE V, Abbott Vascular, Santa Clara, CA, USA) have been
demonstrated in pre-marketing and post-marketing studies with low rates of target
lesion revascularization (TLR), major cardiac adverse events and stent thrombosis
(ST). However, these results were mainly obtained in populations of European
heritage. SEEDS is the first study in China to evaluate XIENCE V’s performance
in Chinese patients with complex lesions.
Methods: This is a prospective, multicenter registry designed to enroll up to 1900
patients with long lesions or small vessel/multivessel coronary disease at 45 sites in
Mainland China, Taiwan and Macao. The primary endpoint is ischemia-driven target
vessel failure (TVF) at 12-month. Clinical follow-up is at 30 days, 6, 12 and 24 months.
All clinical endpoints are adjudicated by independent clinicians and 100% of data are
monitored. In this analysis, descriptive statistics are provided for baseline characteristics
and clinical endpoints by an independent statistical commission.
Results: A total of 365 (19.2%) small vessel patients, 781 (41.1%) long lesion patients,
and 754 (39.7%) multivessel patients with 2825 lesions were treated. Clinical, device and
lesion success rates were 99.47%, 99.95%, and 99.96% respectively. The table below
shows baseline characteristics and 30-day clinical outcomes.
Table: Baseline Characteristics and 30-Day Clinical Outcome
Baseline
Characteristics
(N1,900)
Age (years) 59.59 9.50
Diabetes 27.94%
Current smoker 42.42%
Hypertension 64.35%
Hyperlipidemia 37.33%
Prior MI 25.11%
% Pts with  2 Stents/Lesion 31.22%
Total stent length/lesion
(mm)
22.50 5.49
Clinical Endpoint Results at 30 Days
Small
Vessel
Long
Lesion
Multivessel
Disease All
(n365) (n781) (n754) (n1,900)
Death 0.00% 0.00% 0.27% 0.11%
Cardiac
death
0.00% 0.00% 0.27% 0.11%
MI 2.47% 2.56% 4.11% 3.16%
Q-wave MI 0.27% 0.38% 0.40% 0.37%
Non Q-wave
MI
2.19% 2.18% 3.71% 2.79%
TLR 0.0% 0.0% 0.27% 0.11%
TVF 2.47% 2.56% 4.77% 3.42%
Acute ST
(Def/Prob)
0.00% 0.26% 0.27% 0.21%
Subacute
ST(Def/
Prob)
0.55% 0.00% 0.40% 0.26%
Conclusions: In this large, multicenter, real-world study of Chinese population with
complex lesion subsets, XIENCE V demonstrated low rates of ST, TLR and TVF at
30-day. Long-term results will document the safety and effectiveness of XIENCE V in
high risk cohorts with long lesion and small vessel/multivessel disease from clinical
settings in China. 6-month results will be available at TCT Miami.
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Background: The SPIRIT PRIME trial demonstrated the clinical equivalence of the next
generation XIENCE PRIME everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) to the XIENCE V EES at 1 year. Longer-term outcomes with the XIENCE
PRIME stent have not been investigated.
Methods: SPIRIT PRIME, a prospective, pivotal, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME in both core size (CSR) and long length (LLR)
(33 and 38 mm) stent registries. The CSR analyzed 401 patients and the LLR 104 patients.
Treatment of up to 2 de novo lesions in different epicardial vessels was allowed. The
primary endpoint was 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data and in
accordance with FDA requirements. Data were fully monitored and all endpoint events
adjudicated by an independent clinical events committee.
Results: There were 447 target lesions treated in the CSR and 124 in the LLR. Clinical
device success rates were 98.2% in the CSR and 97.6% in the LLR. Female and diabetic
subjects were 29.7% and 34.9% in the CSR and 37.5% and 35.6%, in the LLR,
respectively. Elderly subjects (65 years old) comprised 41.6% of the CSR and 46.2% of
the LLR. The Table shows outcomes through 2 years.
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Outcome
XIENCE PRIME Observed Rate
CSR (N401)
XIENCE PRIME Observed Rate
LLR (N104)
One Year Two Years One Year Two Years
TLF (per WHO) 4.5% (18/399) 6.4% (25/392) 7.7% (8/104) 9.6% (10/104)
TLF (per ARC) 6.5% (26/399) 8.4% (33/392) 12.5% (13/104) 14.4% (15/104)
Cardiac Death 0.3% (1/399) 0.5% (2/392) 0.0% (0/104) 0.0% (0/104)
All MI (per
WHO)
1.8% (7/399) 2.0% (8/392) 4.8% (5/104) 5.8% (6/104)
All MI (per
ARC)
4.5% (18/399) 5.9% (23/392) 10.6% (11/104) 11.5% (12/104)
TV-MI (per
WHO)
1.8% (7/399) 1.8% (7/392) 4.8% (5/104) 4.8% (5/104)
TV-MI (per
ARC)
4.0% (16/399) 4.6% (18/392) 10.6% (11/104) 10.6% (11/104)
CI-TLR 2.5% (10/399) 4.1% (16/392) 2.9% (3/104) 4.8% (5/104)
ARC-Defined
Stent
Thrombosis
(Definite/
Probable)
0.5% (2/399) 0.5% (2/386) 0.0% (0/104) 0.0% (0/100)
Notes: -
N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at
least one XIENCE PRIME stent and had cardiac enzyme data between 8 hours post
index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI or clinically indicated TLR.
- Time frame includes follow-up window (1-year: 365  28 days, 2-year: 730  28
days).
- TLF from hierarchical counts; other outcomes from non-hierarchical counts.
- WHO: World Health Organization.
- ARC: Academic Research Consortium.
Conclusions: The SPIRIT PRIME study demonstrated sustained 2-year safety and
efficacy of the new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates
in both core size and long lesion cohorts and no new ARC definite/probable ST events in
either arm.
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Background: This study was sought to investigate the impact of complete revascular-
ization (CR) vs. incomplete revascularization (IR) on long-term outcomes in patients with
multivessel coronary disease (MVD) in current practice of percutaneous coronary
intervention (PCI).
Methods: Between April 2004 and November 2010, 7376 consecutive patients with
MVD underwent PCI at our center. Patients who underwent prior CABG and those who
had an acute myocardial infarction (MI) within 24 hours before revascularization or
presented with cardiogenic shock were excluded.
Results: Among 7065 patients with MVD undergoing PCI treatment, angiographic CR
was performed in 1188 patients (16.8%), and proximal CR in 2053 patients (29.1%). The
study found that either angiographic or proximal IR were associated with significantly
higher estimated 3-year rate of cardiac death (2.55% vs. 1.13%, log-rank p0.016; and
2.70% vs. 1.43%, log-rank p0.024; respectively). After adjustment for differences in
baseline characteristics between IR and CR patients, angiographic IR was associated with
a significantly higher rate of cardiac death (adjusted hazards ratio [HR]: 2.56, 95%
confidence interval [CI]: 1.03 to 6.41) while proximal IR was associated with a
numerically higher rate of cardiac death (adjusted HR: 1.72, 95% CI: 0.93 to 3.17). For
the subgroup of 2-vessel IR with total occlusion, either angiographic or proximal IR
patients had significantly higher rate of cardiac death (adjusted HR: 4.25, 95% CI: 1.50 to
12.09; and adjusted HR: 3.02, 95% CI: 1.40 to 6.52; respectively).
Conclusions: Compared with IR, patients with CR had better clinical outcomes,
especially when only single vessels were treated, supporting CR as first choice for patients
with MVD.
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Background: PCI stent inflation pressure correlates to angiographic lumen improvement
and stent expansion but the relation to outcome is not clarified. Using comprehensive
registry data our aim was to evaluate how stent inflation pressure influences restenosis and
stent thrombosis following PCI.
Methods: We evaluated all consecutive coronary stent implantations in Sweden from
January 1, 2008, to October 26, 2011 using data from the Swedish Coronary Angiography
and Angioplasty Registry (SCAAR). We used logistic regression and Cox proportional
hazard modeling to estimate risk of outcomes with different balloon pressures.
Results: In total, 93 697 stents were eligible for analysis and divided into five different
pressure interval groups: 15 atm, 16-17 atm, 18-19 atm, 20-21 atm and 22 atm. The
risks of stent thrombosis (Fig.) and restenosis were significantly higher in the 15 atm,
18-19 atm and 22 atm groups (but not in the 16-17 atm group) compared to the 20-21
atm group. Post-dilatation was associated with a higher restenosis risk ratio (RR) of 1.22
(95% confidence interval (CI) 1.14-1.32, P0.001) but stent thrombosis did not differ
statistically between procedures with or without post-dilatation.
Conclusions: Our retrospective study identified a possible optimal stent inflation pressure
of 20-21 atm during PCI which was associated with a lower risk of stent thrombosis and
restenosis. Post-dilatation might increase restenosis risk.
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Background: Long coronary lesions are a risk factor for increased restenosis and event
rates following coronary stenting. The PLATINUM Long Lesion study evaluates the
PROMUS Element platinum chromium everolimus-eluting stent (Boston Scientific,
Natick, MA) for the treatment of long coronary lesions. Two year results have not yet
been reported.
Methods: The prospective, single-arm PLATINUM Long Lesion (LL) study enrolled
102 patients at 30 clinical sites. Patients had angina pectoris or documented silent
ischemia. One de novo target lesion24 to34mm long with reference diameter2.50
to 4.25mm could be treated with a 32 or 38mm stent. A lesion in a different epicardial
vessel could be treated with a non-study treatment before the target lesion. Exclusion
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